Cargando…

Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis

BACKGROUND: Promoter hypermethylation of Wnt inhibitory factor-1 (WIF-1)—a tumor suppressor gene—has been detected in several types of human tumors. However, the association between WIF-1 promoter hypermethylation and lung cancer remains to be elucidated. Therefore, we conducted this study to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yu, Li, Xia, Jiang, Yiming, Xu, Yufen, Song, Binbin, Zhou, Qiang, Liang, Xiaodong, Yang, Xinmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265994/
https://www.ncbi.nlm.nih.gov/pubmed/27930522
http://dx.doi.org/10.1097/MD.0000000000005433
_version_ 1782500383076122624
author Zheng, Yu
Li, Xia
Jiang, Yiming
Xu, Yufen
Song, Binbin
Zhou, Qiang
Liang, Xiaodong
Yang, Xinmei
author_facet Zheng, Yu
Li, Xia
Jiang, Yiming
Xu, Yufen
Song, Binbin
Zhou, Qiang
Liang, Xiaodong
Yang, Xinmei
author_sort Zheng, Yu
collection PubMed
description BACKGROUND: Promoter hypermethylation of Wnt inhibitory factor-1 (WIF-1)—a tumor suppressor gene—has been detected in several types of human tumors. However, the association between WIF-1 promoter hypermethylation and lung cancer remains to be elucidated. Therefore, we conducted this study to evaluate the clinical significance of WIF-1 promoter hypermethylation in lung cancer. METHODS: A comprehensive literature search was conducted to obtain eligible studies. The combined odds ratios (ORs) or hazard ratios and 95% confidence intervals were used to estimate the strength of associations. RESULTS: A total of 8 eligible publications with 626 cases and 512 controls were included in our study. The combined ORs revealed that WIF-1 promoter hypermethylation was significantly higher in lung cancer than in controls (OR 10.53, P < 0.001). Moreover, WIF-1 promoter hypermethylation was significantly associated with smoking behavior (OR 1.88, P = 0.002). No significant correlation was found between WIF-1 promoter hypermethylation and sex status, age status, tumor stage, and pathological types in cancer. Multivariate analysis results indicated the absence of correlation between WIF-1 promoter hypermethylation and with relapse-free survival and overall survival. Subgroup analysis by sample type demonstrated that promoter hypermethylation of WIF-1 was significantly associated with an increased risk of lung cancer in the tissue (OR 7.89, P < 0.001), blood (OR 21.83, P = 0.034), and pleural effusion subgroups (OR 157.43, P = 0.001). CONCLUSIONS: Promoter hypermethylation of WIF-1 may play a crucial role in lung cancer carcinogenesis. It may be a noninvasive biomarker using blood or pleural effusion detection. WIF-1 promoter hypermethylation is correlated with smoking behavior, but not with sex status, age status, tumor stage, pathological types, and the prognosis of lung cancer patients in terms of relapse-free survival and overall survival. More investigations, including a larger number of subjects, are required to further confirm the findings of our analysis.
format Online
Article
Text
id pubmed-5265994
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-52659942017-02-06 Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis Zheng, Yu Li, Xia Jiang, Yiming Xu, Yufen Song, Binbin Zhou, Qiang Liang, Xiaodong Yang, Xinmei Medicine (Baltimore) 5700 BACKGROUND: Promoter hypermethylation of Wnt inhibitory factor-1 (WIF-1)—a tumor suppressor gene—has been detected in several types of human tumors. However, the association between WIF-1 promoter hypermethylation and lung cancer remains to be elucidated. Therefore, we conducted this study to evaluate the clinical significance of WIF-1 promoter hypermethylation in lung cancer. METHODS: A comprehensive literature search was conducted to obtain eligible studies. The combined odds ratios (ORs) or hazard ratios and 95% confidence intervals were used to estimate the strength of associations. RESULTS: A total of 8 eligible publications with 626 cases and 512 controls were included in our study. The combined ORs revealed that WIF-1 promoter hypermethylation was significantly higher in lung cancer than in controls (OR 10.53, P < 0.001). Moreover, WIF-1 promoter hypermethylation was significantly associated with smoking behavior (OR 1.88, P = 0.002). No significant correlation was found between WIF-1 promoter hypermethylation and sex status, age status, tumor stage, and pathological types in cancer. Multivariate analysis results indicated the absence of correlation between WIF-1 promoter hypermethylation and with relapse-free survival and overall survival. Subgroup analysis by sample type demonstrated that promoter hypermethylation of WIF-1 was significantly associated with an increased risk of lung cancer in the tissue (OR 7.89, P < 0.001), blood (OR 21.83, P = 0.034), and pleural effusion subgroups (OR 157.43, P = 0.001). CONCLUSIONS: Promoter hypermethylation of WIF-1 may play a crucial role in lung cancer carcinogenesis. It may be a noninvasive biomarker using blood or pleural effusion detection. WIF-1 promoter hypermethylation is correlated with smoking behavior, but not with sex status, age status, tumor stage, pathological types, and the prognosis of lung cancer patients in terms of relapse-free survival and overall survival. More investigations, including a larger number of subjects, are required to further confirm the findings of our analysis. Wolters Kluwer Health 2016-12-09 /pmc/articles/PMC5265994/ /pubmed/27930522 http://dx.doi.org/10.1097/MD.0000000000005433 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 5700
Zheng, Yu
Li, Xia
Jiang, Yiming
Xu, Yufen
Song, Binbin
Zhou, Qiang
Liang, Xiaodong
Yang, Xinmei
Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis
title Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis
title_full Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis
title_fullStr Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis
title_full_unstemmed Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis
title_short Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis
title_sort promoter hypermethylation of wnt inhibitory factor-1 in patients with lung cancer: a systematic meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265994/
https://www.ncbi.nlm.nih.gov/pubmed/27930522
http://dx.doi.org/10.1097/MD.0000000000005433
work_keys_str_mv AT zhengyu promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT lixia promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT jiangyiming promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT xuyufen promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT songbinbin promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT zhouqiang promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT liangxiaodong promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis
AT yangxinmei promoterhypermethylationofwntinhibitoryfactor1inpatientswithlungcancerasystematicmetaanalysis